- Home
- ACLX
ACLX
Arcellx Inc.
as 11-15-2024 4:00pm EST
Arcellx Inc is a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | REDWOOD CITY |
| Market Cap: | 5.3B | IPO Year: | 2022 |
| Target Price: | $103.67 | AVG Volume (30 days): | 667.5K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 14 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.77 | EPS Growth: | N/A |
| 52 Week Low/High: | $46.42 - $107.37 | Next Earning Date: | 11-07-2024 |
| Revenue: | $155,818,000 | Revenue Growth: | 230.33% |
| Revenue Growth (this year): | 20.54% | Revenue Growth (next year): | -6.03% |
Stock Insider Trading Activity of Arcellx Inc. (ACLX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Patel Kavita | ACLX | Director | Oct 22 '24 | Sell | $89.69 | 1,500 | $134,535.00 | 0 | |
| Patel Kavita | ACLX | Director | Oct 1 '24 | Sell | $82.24 | 1,500 | $123,360.00 | 0 | |
| Gilson Michelle | ACLX | CHIEF FINANCIAL OFFICER | Sep 17 '24 | Sell | $77.69 | 15,000 | $1,165,879.57 | 15,641 | |
| Patel Kavita | ACLX | Director | Sep 10 '24 | Sell | $74.41 | 1,500 | $111,615.00 | 0 | |
| Heery Christopher | ACLX | CHIEF MEDICAL OFFICER | Sep 5 '24 | Sell | $70.02 | 3,421 | $239,526.10 | 9,278 | |
| Heery Christopher | ACLX | CHIEF MEDICAL OFFICER | Sep 3 '24 | Sell | $68.08 | 27,451 | $1,840,053.23 | 9,278 | |
| Heery Christopher | ACLX | CHIEF MEDICAL OFFICER | Aug 26 '24 | Sell | $70.98 | 21,684 | $1,542,273.63 | 9,278 | |
| Patel Kavita | ACLX | Director | Aug 20 '24 | Sell | $65.88 | 1,500 | $98,820.00 | 0 |
Latest Arcellx Inc. News
ACLX Breaking Stock News: Dive into ACLX Ticker-Specific Updates for Smart Investing
Zacks
4 days ago
Are You Looking for a Top Momentum Pick? Why Arcellx, Inc. (ACLX) is a Great Choice
MT Newswires
5 days ago
Arcellx Insider Sold Shares Worth $1,242,170, According to a Recent SEC Filing
Simply Wall St.
8 days ago
Arcellx Third Quarter 2024 Earnings: Misses Expectations
Zacks
9 days ago
Is Arcellx (ACLX) Outperforming Other Medical Stocks This Year?
Zacks
10 days ago
Arcellx, Inc. (ACLX) Reports Q3 Loss, Lags Revenue Estimates
Business Wire
10 days ago
Arcellx Provides Third Quarter 2024 Financial Results and Business Highlights
TipRanks
11 days ago
Arcellx price target raised to $106 from $81 at Morgan Stanley
Zacks
11 days ago
Arcellx (ACLX) Stock Jumps 6.7%: Will It Continue to Soar?
Compare ACLX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ACLX Arcellx Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.